Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

Compare

894 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

APLS Analyst Ratings

Moderate Buy

11 Buy

8 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Apellis

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

APLS Stock 12 Month Forecast

Average Price Target

$35.47

▲(91.63%Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Apellis Pharmaceuticals in the last 3 months. The average price target is $35.47 with a high forecast of $57.00 and a low forecast of $18.00. The average price target represents a 91.63% change from the last price of $18.51.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","58":"$58","27.25":"$27.3","37.5":"$37.5","47.75":"$47.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$57.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,27.25,37.5,47.75,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.14,22.052307692307693,24.964615384615385,27.876923076923077,30.78923076923077,33.70153846153846,36.613846153846154,39.526153846153846,42.43846153846154,45.35076923076923,48.26307692307692,51.175384615384615,54.08769230769231,{"y":57,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.14,20.396153846153847,21.652307692307694,22.908461538461538,24.164615384615384,25.42076923076923,26.676923076923075,27.93307692307692,29.189230769230768,30.445384615384615,31.701538461538462,32.957692307692305,34.21384615384615,{"y":35.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.14,19.052307692307693,18.964615384615385,18.876923076923077,18.78923076923077,18.701538461538462,18.613846153846154,18.526153846153846,18.43846153846154,18.35076923076923,18.263076923076923,18.175384615384615,18.087692307692308,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.25,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.29,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.9,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.91,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$57.00

Average Price Target$35.47

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$19.5

Hold

5.35%

Upside

Reiterated

06/03/25

Apellis Pharmaceuticals' stock score reflects strong revenue growth and strategic FDA milestones tempered by ongoing profitability challenges and negative market momentum. The stock's valuation is affected by its negative earnings, and while corporate governance improvements are positive, they do not significantly alter the current financial outlook.

Derek ArchilaWells Fargo

Wells Fargo

$26→$29

Hold

56.67%

Upside

Reiterated

06/02/25

Cautious Hold on Apellis Pharmaceuticals Amid Uncertainties with Pegcetacoplan Launch and Financial Stability

Biren AminPiper Sandler

Piper Sandler

$26

Hold

40.46%

Upside

Reiterated

05/28/25

Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)

Yigal NochomovitzCiti

Citi

$49→$41

Buy

121.50%

Upside

Reiterated

05/22/25

Apellis Pharmaceuticals (APLS) PT Lowered to $41 at Citi, Opens 90-Day Upside Catalyst WatchCiti analyst Yigal Nochomovitz lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $41.00 (from $49.00) while maintaining a Buy rating.

Anupam RamaJ.P. Morgan

J.P. Morgan

$45→$35

Buy

89.09%

Upside

Reiterated

05/22/25

Analysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Apellis Pharmaceuticals (APLS)

Tazeen AhmadBank of America Securities

Bank of America Securities

$23

Hold

24.26%

Upside

Reiterated

05/14/25

Bank of America Securities Sticks to Their Hold Rating for Apellis Pharmaceuticals (APLS)

Graig SuvannavejhMizuho Securities

Mizuho Securities

$30→$20

Hold

8.05%

Upside

Reiterated

05/14/25

Analysts Offer Insights on Healthcare Companies: Editas Medicine (NASDAQ: EDIT), Apellis Pharmaceuticals (NASDAQ: APLS) and Argenx Se (NASDAQ: ARGX)

Steven SeedhouseCantor Fitzgerald

Cantor Fitzgerald

$75→$52

Buy

180.93%

Upside

Reiterated

05/09/25

Raymond James downgrades Apellis Pharmaceuticals (APLS) to Outperform

Ryan DeschnerRaymond James

Raymond James

$52

Buy

180.93%

Upside

Downgraded

05/09/25

Apellis downgraded to Outperform from Strong Buy at Raymond JamesApellis downgraded to Outperform from Strong Buy at Raymond James

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$57

Buy

207.94%

Upside

Reiterated

05/08/25

Optimistic Growth Potential for Apellis Pharmaceuticals Despite Temporary Setbacks

Greg HarrisonScotiabank

Scotiabank

$31→$20

Hold

8.05%

Upside

Reiterated

05/08/25

Scotiabank Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)

Judah FrommerMorgan Stanley

Morgan Stanley

$30→$25

Hold

35.06%

Upside

Reiterated

05/08/25

Apellis Pharmaceuticals (APLS) PT Lowered to $25 at Morgan StanleyMorgan Stanley analyst Judah Frommer lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $25.00 (from $30.00) while maintaining a Equalweight rating.

Colleen M. KusyRobert W. Baird

Robert W. Baird

$55→$47

Buy

153.92%

Upside

Reiterated

05/08/25

Apellis price target lowered to $47 from $55 at BairdApellis price target lowered to $47 from $55 at Baird

Phil NadeauTD Cowen

TD Cowen

$60→$50

Buy

170.12%

Upside

Reiterated

05/07/25

Apellis Pharmaceuticals: Buy Rating Reaffirmed Amid Growth Potential and Market Leadership in GA

Lachlan Hanbury BrownWilliam Blair

William Blair

―

Buy

―

Reiterated

05/07/25

Apellis Pharmaceuticals: Long-term Growth Potential and Market Recovery Underpin Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$19.5

Hold

5.35%

Upside

Reiterated

06/03/25

Derek ArchilaWells Fargo

Wells Fargo

$26→$29

Hold

56.67%

Upside

Reiterated

06/02/25

Cautious Hold on Apellis Pharmaceuticals Amid Uncertainties with Pegcetacoplan Launch and Financial Stability

Biren AminPiper Sandler

Piper Sandler

$26

Hold

40.46%

Upside

Reiterated

05/28/25

Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)

Yigal NochomovitzCiti

Citi

$49→$41

Buy

121.50%

Upside

Reiterated

05/22/25

Anupam RamaJ.P. Morgan

J.P. Morgan

$45→$35

Buy

89.09%

Upside

Reiterated

05/22/25

Analysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Apellis Pharmaceuticals (APLS)

Tazeen AhmadBank of America Securities

Bank of America Securities

$23

Hold

24.26%

Upside

Reiterated

05/14/25

Bank of America Securities Sticks to Their Hold Rating for Apellis Pharmaceuticals (APLS)

Graig SuvannavejhMizuho Securities

Mizuho Securities

$30→$20

Hold

8.05%

Upside

Reiterated

05/14/25

Analysts Offer Insights on Healthcare Companies: Editas Medicine (NASDAQ: EDIT), Apellis Pharmaceuticals (NASDAQ: APLS) and Argenx Se (NASDAQ: ARGX)

Steven SeedhouseCantor Fitzgerald

Cantor Fitzgerald

$75→$52

Buy

180.93%

Upside

Reiterated

05/09/25

Raymond James downgrades Apellis Pharmaceuticals (APLS) to Outperform

Ryan DeschnerRaymond James

Raymond James

$52

Buy

180.93%

Upside

Downgraded

05/09/25

Apellis downgraded to Outperform from Strong Buy at Raymond JamesApellis downgraded to Outperform from Strong Buy at Raymond James

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$57

Buy

207.94%

Upside

Reiterated

05/08/25

Optimistic Growth Potential for Apellis Pharmaceuticals Despite Temporary Setbacks

Greg HarrisonScotiabank

Scotiabank

$31→$20

Hold

8.05%

Upside

Reiterated

05/08/25

Scotiabank Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)

Judah FrommerMorgan Stanley

Morgan Stanley

$30→$25

Hold

35.06%

Upside

Reiterated

05/08/25

Colleen M. KusyRobert W. Baird

Robert W. Baird

$55→$47

Buy

153.92%

Upside

Reiterated

05/08/25

Apellis price target lowered to $47 from $55 at BairdApellis price target lowered to $47 from $55 at Baird

Phil NadeauTD Cowen

TD Cowen

$60→$50

Buy

170.12%

Upside

Reiterated

05/07/25

Apellis Pharmaceuticals: Buy Rating Reaffirmed Amid Growth Potential and Market Leadership in GA

Lachlan Hanbury BrownWilliam Blair

William Blair

―

Buy

―

Reiterated

05/07/25

Apellis Pharmaceuticals: Long-term Growth Potential and Market Recovery Underpin Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Apellis Pharmaceuticals

1 Month

xxx

Success Rate

18/28 ratings generated profit

Average Return

+4.04%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +4.04% per trade.

3 Months

xxx

Success Rate

17/27 ratings generated profit

Average Return

+3.41%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.96% of your transactions generating a profit, with an average return of +3.41% per trade.

1 Year

Yigal NochomovitzCiti

Success Rate

14/30 ratings generated profit

Average Return

+1.67%

reiterated a buy rating 16 days ago

Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +1.67% per trade.

2 Years

xxx

Success Rate

14/27 ratings generated profit

Average Return

-2.38%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 51.85% of your transactions generating a profit, with an average return of -2.38% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

APLS Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, APLS has received 14 Buy Ratings, 18 Hold Ratings, and 0 Sell Ratings. APLS average Analyst price target in the past 3 months is 35.47.

Each month's total comprises the sum of three months' worth of ratings.

APLS Financial Forecast

APLS Earnings Forecast

Next quarter’s earnings estimate for APLS is -$0.47 with a range of -$0.75 to -$0.27. The previous quarter’s EPS was -$0.74. APLS beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year APLS has Outperformed its overall industry.

APLS Sales Forecast

Next quarter’s sales forecast for APLS is $187.96M with a range of $167.18M to $217.40M. The previous quarter’s sales results were $166.80M. APLS beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year APLS has Outperformed its overall industry.

APLS Stock Forecast FAQ

What is APLS’s average 12-month price target, according to analysts?

Based on analyst ratings, Apellis Pharmaceuticals Inc’s 12-month average price target is 35.47.

What is APLS’s upside potential, based on the analysts’ average price target?

Apellis Pharmaceuticals Inc has 91.63% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is APLS a Buy, Sell or Hold?

Apellis Pharmaceuticals Inc has a consensus rating of Moderate Buy which is based on 11 buy ratings, 8 hold ratings and 0 sell ratings.

What is Apellis Pharmaceuticals Inc’s price target?

The average price target for Apellis Pharmaceuticals Inc is 35.47. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $57.00 ,the lowest forecast is $18.00. The average price target represents 91.63% Increase from the current price of $18.51.

What do analysts say about Apellis Pharmaceuticals Inc?

Apellis Pharmaceuticals Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of APLS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

APLS Analyst Ratings

APLS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Apellis Pharmaceuticals

APLS Analyst Recommendation Trends

APLS Financial Forecast

APLS Earnings Forecast

APLS Sales Forecast

APLS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts